Skip to content

NEUPHARMA

Absorbed by BA PHARMA KBO/BCE: BE 0840.662.376 subsidiary of BA PHARMA
NEUPHARMA
Follow Report

Last board

1 director, last change in 2022
Anne Baelen
Director
since 31-10-2022
listed in the 2022 annual accounts, filed on 06-07-2023

Office holders in the KBO →

Mandates through the years

4 names, the dashed line is today
Anne Baelen
Director
Christine Degardin
Director
Jean Henin
Director
Jean-Paul Brohée
Director
BoardEarliermandate already running before its first mention
Mandates as a list
  • Anne Baelen
    • Director, from 31-10-2022 to date
  • Christine Degardin
    • Director, from before 31-12-2021 to 31-10-2022
  • Jean Henin
    • Director, from 10-11-2011 to 31-10-2022
  • Jean-Paul Brohée
    • Director, from 10-11-2011 to 31-10-2022

Control

Parent
BA PHARMA
Equity €146,387
Profit €689 in 2025 (profit €1,179 in 2024)
Checked score 55
Source: deed 11-10-2023
100%
This company
NEUPHARMA
Equity €298,630
Profit €43,371 in 2022

Capital

Contribution
€49,868.62
Source
2022 annual accounts

Capital transactions

Shareholders according to the deeds
Stated in the deed deed of 28-02-2023 ↗
Capital over time
  1. 19-02-2018 Capital reduction of €90,000 · to €49,500 · repaid to the shareholders

Next steps

See who ran this company and where its registered office was, on a date of your choice.Company as of a date See what became of the directors' other companies.Supplier due diligence

We would like to set cookies. That happens only with your consent. What we measure